X

Trial Profile

Efficacy and Safety of Donafenib in Patients With Previously Treated Metastatic Colorectal Cancer:a Controlled,Multicentre,Randomised, Phase 3 Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donafenib (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Registrational; Therapeutic Use
Sponsors Suzhou Zelgen Biopharmaceuticals

Most Recent Events

28 Nov 2022 Status changed from recruiting to completed.
19 May 2021 Planned number of patients changed from 510 to 536.
19 May 2021 Planned End Date changed from 1 Oct 2020 to 30 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com